Release Date: September 30, 2025
Expiration Date: September 30, 2026
Activity Overview
While treatment options for advanced non–small cell lung cancer (NSCLC) have expanded, challenges remain in overcoming resistance and optimizing outcomes across diverse patient populations. Novel therapies, such as bispecific antibodies and antibody-drug conjugates (ADCs), offer promising new mechanisms and are reshaping the future of care.
This certified CME satellite symposium, held in conjunction with the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, features expert-led presentations and interactive discussions on emerging clinical trial data, real-world applications, and future directions for bispecifics and ADCs. Attendees will gain practical guidance on integrating these agents into personalized treatment strategies for advanced NSCLC.
This educational activity is an archive of the live virtual symposium held on September 6, 2025.
Target Audience
This educational activity is directed toward physicians, pathologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the diagnosis and treatment of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate the latest evidence and disease-/patient-specific characteristics into personalized treatment plans for advanced NSCLC
- Describe the unique mechanisms of emerging bispecific antibodies and ADCs being investigated for the treatment of advanced NSCLC
- Assess the implications of recent clinical trial evidence on the potential roles for emerging bispecific antibodies and ADCs in advanced NSCLC
Sandip Patel, MD, FASCO
Professor, Medical Oncology
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Experimental Therapeutics Program
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
University of California San Diego
San Diego, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Johnson & Johnson, Pfizer; Grant/Research Funding: A2bio, Amgen, AstraZeneca, Bristol-Myers Squibb, Corbus, Eli Lilly, Fate, Gilead, Merck, Pfizer, Roche/Genentech, TScan
Myung-Ju Ahn, MD
Professor
Division of Hemato-Oncology
Department of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, South Korea
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Genexine, Lilly, Merck, MSD, Novartis, ONO, Roche, Takeda, Voronoi, Yuhan
Giannis Mountzios, MD, MSc, PhD
Medical Oncologist
Director, 4th Oncology Clinic and Clinical Trials Department
Henry Dunant Hospital Center
ONCOLIFE Network Founder
Athens, Greece
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Amgen, Bristol Myers Squibb, Daiichi Sankyo, Demo, GSK, Merck, Merck Sharp & Dohme, Novartis, Roche, Summit Therapeutics, Takeda
Zofia Piotrowska, MD, MHS
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Bayer, Black Diamond Therapeutics, Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Janssen, Natera, Taiho, Takeda, Tubulis; Grant/Research Funding (to institution): AbbVie, AstraZeneca, Blueprint, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Nuvalent, Spectrum, SystImmune, Takeda, Tesaro/GSK
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here